Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PCA062 |
Synonyms | |
Therapy Description |
PCA062 is an antibody drug conjugate comprised of maytansinoid DM1 and a monoclonal antibody specific to CDH3, which may lead to cytotoxicity of CHD3-expressing tumor cells (Cancer Res 2015;75(15 Suppl):Abstract nr 1682). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PCA062 | PCA062 is an antibody drug conjugate comprised of maytansinoid DM1 and a monoclonal antibody specific to CDH3, which may lead to cytotoxicity of CHD3-expressing tumor cells (Cancer Res 2015;75(15 Suppl):Abstract nr 1682). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | 5 |